From Trial to Treatment: Using Modern Evidence, Expert Insight, and Practice Simulation to Navigate the Integration of Bispecific Antibodies into the Care of Patients with Multiple Myeloma

The rapidly evolving multiple myeloma (MM) treatment landscape has created unprecedented opportunities, while introducing new complexities for clinicians caring for patients with relapsed/refractory (R/R) disease. In just a few years, bispecific antibodies (BsAbs) have emerged as highly effective treatment options, yet many community oncology professionals remain uncertain about how to identify appropriate candidates, sequence these therapies, manage unique toxicities, and navigate the logistical demands associated with their use. Recent evidence reveals persistent gaps in clinician experience, confidence, and application of evidence-based strategies related to BsAb therapy, underscoring an urgent need for practical, implementation-focused education.

Designed to bridge the gap between evidence and practice, this innovative educational experience combines expert-guided analysis of real-world patient cases with immersive simulation-based learning. Participants will move beyond passive education to actively apply clinical decision-making skills, receive personalized coaching, and explore solutions to common challenges encountered in routine care. Through this interactive approach, learners will gain the confidence, competence, and practical tools needed to effectively integrate BsAbs into contemporary MM management.

At the conclusion of this activity, learners will be able to better:

• Identify patients with RRMM eligible for targeted BsAb therapy to appropriately individualize therapeutic selection
• Utilize randomized controlled trials (RCTs) and real-world data (RWD) with BsAbs in patients with RRMM to effectively implement these agents across clinical practice settings
• Evaluate mitigation strategies for adverse events (AEs) in patients with RRMM prescribed targeted BsAbs to ensure safe and continuous treatment
• Employ practices to address the unique logistical challenges associated with BsAb treatment for RRMM to address access barriers for patients receiving care in community-based settings

Supported by educational grants from Johnson & Johnson and Regeneron Pharmaceuticals, Inc.

Medical and hematologic oncologists, hematology-oncology fellows, hematology-oncology physician associates (PAs) and nurse practitioners (NPs), oncology nurses, and oncology pharmacists

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Costello reports the following financial relationships:

Advisory Board: Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Kite/Arcellx; and OpnaBio

Consultant: AstraZeneca; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Pfizer Inc.

Research Support: AstraZeneca; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda; and Poseida Therapeutics, Inc

Dr. Richter reports the following financial relationships:

Consultant: AbbVie Inc; Bristol-Myers Squibb; Forus Therapeutics Inc.;Genentech, Inc; Janssen Pharmaceuticals, Inc.; Karyopharm; Kite/Arcellx; Menarini Group; Pfizer Inc.; Regeneron Pharmaceuticasl Inc; Sanofi-Genzyme; and Takeda Pharmaceuticals

Speakers Bureau: Bristol-Myers Squibb; Adaptive Biotechnologies; Janssen Pharmaceuticals, Inc.; Pfizer Inc; and Sanofi-Genzyme

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Sarah Hertich (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

SIM-002-063026-90